Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Aug;4(8):688-90.
doi: 10.1002/emmm.201201509. Epub 2012 Jul 24.

IGF2: the Achilles' heel of p53-deficiency?

Frederic Clermont  1 , David Nittner, Jean-Christophe Marine
Affiliations
Comment

IGF2: the Achilles' heel of p53-deficiency?

Frederic Clermont et al. EMBO Mol Med. 2012 Aug.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Igf2 and Tp53 genetic interactions in mice
Whereas Igf2-deficient males are viable, Igf2-deficiency is lethal in females. Loss of one Trp53 allele is sufficient to partly rescue this lethality. Loss of both Igf2 and p53 expression is not compatible with life.
Figure 2
Figure 2. Targeting the Igf2 pathway in human tumours
The p53 pathway malfunctions in virtually all human cancers. Data reported in Haley et al. indicate that IGF2 LOI promotes tumourigenesis by inactivating p53 in tumours that retain wild-type TP53. Targeting IGF2 signalling in this context may lead to reactivation of p53 tumour suppressor function. Loss of Igf2 significantly affects the progression of p53-deficient tumours in mice. This observation predicts that IGF2 targeting will reduce the fitness of tumours in which p53 function is compromised as a result of TP53 inactivating mutations or deletions.
See this image and copyright information in PMC

Comment on

References

    1. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol. 1995;5:931–936. - PubMed
    1. Avnet S, Perut F, Salerno M, Sciacca L, Baldini N. Insulin receptor isoforms are differently expressed during human osteoblastogenesis. Differentiation. 2012;83:242–248. - PubMed
    1. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9:862–873. - PubMed
    1. Christofori G, Naik P, Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature. 1994;369(6479):414–418. - PubMed
    1. Christofori G, Naik P, Hanahan D. Deregulation of both imprinted and expressed alleles of the insulin-like growth factor 2 gene during beta-cell tumorigenesis. Nat Genet. 1995;10:196–201. - PubMed

Substances